PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1005-1009

  Zhang, Xing Guang ^a   Lu, Xiao Feng ^a   Jiao, Xiu Ming ^a   Chen, Bin ^a   Wu, Jin Xiao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Anaplastic thyroid carcinoma; CD44v6; Cell invasion; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Polo like kinase 1; RNA interference

Indexed keywords

CD44V6 ANTIGEN; GELATINASE A; GELATINASE B; POLO LIKE KINASE 1; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIATED THYROID CANCER; FEMALE; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PLK1 GENE; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 84867273309     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.729     Document Type: Article

References (22)

1. van de Weerdt BC and Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle 5: 853-864, 2006.
2. Degenhardt Y and Lampkin T: Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16: 384-389, 2010.
3. Liu YZ, Yu L, Gong DD, et al: Construction of PLK1 siRNA and its effects on proliferation and apoptosis of undifferentiated human thyroid cancer cells. Chin J Endocr Surg 5: 76-79, 2011 (In Chinese).
4. Feng YB, Lin DC, Shi ZZ, et al: Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 124: 578-588, 2009.
5. Zhao CL, Gong L, Li WT and Chen L: Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 136: 9-16, 2010.
6. Evans RP, Dueck G, Sidhu R, et al: Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Leuk Res 35: 1637-1643, 2011.
7. Noriyuki T and Hisashi N: Polo-like kinases (Plks) are prognostic markers for gynecologic malignancies. Cur Womens Health Rev 4: 266-269, 2008.
8. Schmit TL, Zhong WX, Nihal M and Ahmad N: Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 8: 2697-2702, 2009.
9. He ZL, Zheng H, Lin H, et al: Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 15: 4177-4182, 2009.
10. Lan B, Liu BY, Chen XH, et al: Polo like kinase 1 expression and prognostic value in gastric carcinomas. Zhonghua Wei Chang Wai Ke Za Zhi 10: 70-72, 2007 (In Chinese).
11. Zhang Y, Liu Y, Yang YX, et al: The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity. J Exp Clin Cancer Res 28: 130-139, 2009.
12. Salvatore G, Nappi TC, Salerno P, et al: A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67: 10148-10158, 2009.
13. Nappi TC, Salerno P, Zitzelsberger H, et al: Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69: 1916-1923, 2009.
14. Kojic SL, Strugnell SS and Wiseman SM: Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther 11: 387-402, 2011.
15. Thullberg M and Strömblad S: Anchorage-independent cytokinesis as part of oncogenic transformation? Cell Cycle 7: 984-988, 2008.
16. Marshall J: Transwell(®) invasion assays. Methods Mol Biol 769: 97-110, 2011.
17. Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 214: 283-293, 2008.
18. Jung T, Gross W and Zöller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 286: 15862-15874, 2011.
19. Cho Mar K, Eimoto T, Tateyama H, et al: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 48: 286-294, 2006.
20. Tan H, Ye K, Wang Z and Tang H: Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol 38: 528-533, 2008.
21. Buergy D, Weber T, Maurer GD, et al: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125: 894-901, 2009.
22. Rothhut B, Ghoneim C, Antonicelli F and Soula-Rothhut M: Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through focal adhesion kinase. Biochimie 89: 613-624, 2007.